TransMedics Group (NASDAQ:TMDX) Shares Gap Up - What's Next?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares changing hands.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Robert W. Baird lowered their target price on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. TD Cowen reduced their target price on TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a report on Monday, November 18th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Price Performance

The business's fifty day moving average price is $72.08 and its 200 day moving average price is $118.74. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market cap of $1.95 billion, a P/E ratio of 61.72 and a beta of 2.12.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group's revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) EPS. Sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Driehaus Capital Management LLC increased its stake in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock valued at $223,832,000 after buying an additional 202,867 shares during the period. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company's stock worth $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company's stock worth $94,061,000 after purchasing an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. lifted its position in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company's stock worth $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock valued at $42,656,000 after purchasing an additional 6,634 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.